skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Results 1 - 20 of 204  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page
Refined by: Journal Title: M2 Presswire remove subject: Drug Therapy remove
Result Number Material Type Add to My Shelf Action Record Details and Options
1
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia | GSK
Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia | GSK
Material Type:
Newspaper Article 		Add to My Research

Ojjaara (momelotinib) approved in the US as the first and only treatment indicated for myelofibrosis patients with anaemia | GSK

M2 Presswire, 2023-09-18

COPYRIGHT 2023 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
2
Herpes Zoster Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax
Herpes Zoster Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax
Material Type:
Newspaper Article 		Add to My Research

Herpes Zoster Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CPL Biologics, EuBiologics, Moderna, Gene One Life Science, Dynavax

M2 Presswire, 2024-04-15

COPYRIGHT 2024 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
3
Gastrointestinal Stromal Tumor Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | IDRx, Inc
Gastrointestinal Stromal Tumor Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | IDRx, Inc
Material Type:
Newspaper Article 		Add to My Research

Gastrointestinal Stromal Tumor Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | IDRx, Inc

M2 Presswire, 2024-04-05

COPYRIGHT 2024 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
4
Pancreatic Ductal Adenocarcinoma Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Taiho Pharma, Genmab, Bristol-Myers
Pancreatic Ductal Adenocarcinoma Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Taiho Pharma, Genmab, Bristol-Myers
Material Type:
Newspaper Article 		Add to My Research

Pancreatic Ductal Adenocarcinoma Pipeline Assessment: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, Therapeutic Analysis, and Growth Prospects | Taiho Pharma, Genmab, Bristol-Myers

M2 Presswire, 2024-04-04

COPYRIGHT 2024 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
5
Anemia In Chronic Kidney Disease Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, RoA by DelveInsight | Jiangsu HengRui Medicine, Disc Medicine, 3SBio
Anemia In Chronic Kidney Disease Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, RoA by DelveInsight | Jiangsu HengRui Medicine, Disc Medicine, 3SBio
Material Type:
Newspaper Article 		Add to My Research

Anemia In Chronic Kidney Disease Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, RoA by DelveInsight | Jiangsu HengRui Medicine, Disc Medicine, 3SBio

M2 Presswire, 2024-04-03

COPYRIGHT 2024 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
6
Osteoporosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer Inc., Eli Lilly and Company, F. Hoffmann La Roche, Merck Co
Osteoporosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer Inc., Eli Lilly and Company, F. Hoffmann La Roche, Merck Co
Material Type:
Newspaper Article 		Add to My Research

Osteoporosis Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer Inc., Eli Lilly and Company, F. Hoffmann La Roche, Merck Co

M2 Presswire, 2024-04-02

COPYRIGHT 2024 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
7
Global Alzheimer Disease Research Report 2021: Updated Report with Focus on New Drugs, Markets and Competitive Landscape, 2020-2030
Global Alzheimer Disease Research Report 2021: Updated Report with Focus on New Drugs, Markets and Competitive Landscape, 2020-2030
Material Type:
Newspaper Article 		Add to My Research

Global Alzheimer Disease Research Report 2021: Updated Report with Focus on New Drugs, Markets and Competitive Landscape, 2020-2030

M2 Presswire, 2021-06-03

COPYRIGHT 2021 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
8
Hepatocellular Carcinoma Pipeline Analysis 2024 | Clinical Trials, FDA, EMA, and PMDA Approvals | Saronic Biotech, HiFiBiO Therapeutics, Sirnaomics, Exelixis, Tvardi Therapeutics, Portage Biotech
Hepatocellular Carcinoma Pipeline Analysis 2024 | Clinical Trials, FDA, EMA, and PMDA Approvals | Saronic Biotech, HiFiBiO Therapeutics, Sirnaomics, Exelixis, Tvardi Therapeutics, Portage Biotech
Material Type:
Newspaper Article 		Add to My Research

Hepatocellular Carcinoma Pipeline Analysis 2024 | Clinical Trials, FDA, EMA, and PMDA Approvals | Saronic Biotech, HiFiBiO Therapeutics, Sirnaomics, Exelixis, Tvardi Therapeutics, Portage Biotech

M2 Presswire, 2024-03-22

COPYRIGHT 2024 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
9
HER2 Negative Breast Cancer Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisa
HER2 Negative Breast Cancer Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisa
Material Type:
Newspaper Article 		Add to My Research

HER2 Negative Breast Cancer Pipeline Drugs Analysis Report, 2024 Updates: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisa

M2 Presswire, 2024-03-21

COPYRIGHT 2024 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
10
Advanced Ovarian Cancer Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact Therapeutics
Advanced Ovarian Cancer Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact Therapeutics
Material Type:
Newspaper Article 		Add to My Research

Advanced Ovarian Cancer Pipeline Analysis, 2024 Updates | Latest FDA, EMA, and PMDA Approvals | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer Ingelheim, Impact Therapeutics

M2 Presswire, 2024-03-01

COPYRIGHT 2024 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
11
Bladder cancer Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CG Oncology, FKD Therapies, Bristol-Myers Squibb, LintonPharm, ImmunityBio, Hamlet
Bladder cancer Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CG Oncology, FKD Therapies, Bristol-Myers Squibb, LintonPharm, ImmunityBio, Hamlet
Material Type:
Newspaper Article 		Add to My Research

Bladder cancer Pipeline Drugs Analysis Report: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | CG Oncology, FKD Therapies, Bristol-Myers Squibb, LintonPharm, ImmunityBio, Hamlet

M2 Presswire, 2024-01-15

COPYRIGHT 2024 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
12
Tuberculosis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | GlaxoSmithKline, Archivel Farma S.L, Qurient Co., Sequella, Inc., Vaxil
Tuberculosis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | GlaxoSmithKline, Archivel Farma S.L, Qurient Co., Sequella, Inc., Vaxil
Material Type:
Newspaper Article 		Add to My Research

Tuberculosis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | GlaxoSmithKline, Archivel Farma S.L, Qurient Co., Sequella, Inc., Vaxil

M2 Presswire, 2023-12-18

COPYRIGHT 2023 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
13
HER2 Negative Breast Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai
HER2 Negative Breast Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai
Material Type:
Newspaper Article 		Add to My Research

HER2 Negative Breast Cancer Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Hoffmann-La Roche, Angiochem, Bristol-Myers Squibb, Eisai

M2 Presswire, 2023-12-18

COPYRIGHT 2023 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
14
Advanced Ovarian Cancer Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui
Advanced Ovarian Cancer Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui
Material Type:
Newspaper Article 		Add to My Research

Advanced Ovarian Cancer Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui

M2 Presswire, 2023-12-18

COPYRIGHT 2023 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
15
Non-Cystic Fibrosis Bronchiectasis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi
Non-Cystic Fibrosis Bronchiectasis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi
Material Type:
Newspaper Article 		Add to My Research

Non-Cystic Fibrosis Bronchiectasis Pipeline Drugs Analysis Report, 2023: FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi

M2 Presswire, 2023-12-15

COPYRIGHT 2023 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
16
Neuroendocrine Tumors Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus
Neuroendocrine Tumors Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus
Material Type:
Newspaper Article 		Add to My Research

Neuroendocrine Tumors Pipeline Drugs Analysis Report (2023 Updates): FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus

M2 Presswire, 2023-12-14

COPYRIGHT 2023 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
17
Influenza Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, and Growth Prospects | AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc
Influenza Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, and Growth Prospects | AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc
Material Type:
Newspaper Article 		Add to My Research

Influenza Pipeline Assessment, 2023 Updates: FDA, EMA, and PMDA Approvals, Emerging Drugs, Clinical Trials, and Growth Prospects | AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc

M2 Presswire, 2023-12-08

COPYRIGHT 2023 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
18
Pulmonary Hypertension Pipeline Review 2023: Comprehensive Analysis of Emerging Medications, Recent FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Prospects by DelveInsight
Pulmonary Hypertension Pipeline Review 2023: Comprehensive Analysis of Emerging Medications, Recent FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Prospects by DelveInsight
Material Type:
Newspaper Article 		Add to My Research

Pulmonary Hypertension Pipeline Review 2023: Comprehensive Analysis of Emerging Medications, Recent FDA, EMA, and PMDA Approvals, Clinical Trials, and Treatment Prospects by DelveInsight

M2 Presswire, 2023-12-08

COPYRIGHT 2023 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
19
Exploring the Gout Pipeline in 2023: FDA Approvals, Promising Therapies, and Key Players Identified by DelveInsight | TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics plc
Exploring the Gout Pipeline in 2023: FDA Approvals, Promising Therapies, and Key Players Identified by DelveInsight | TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics plc
Material Type:
Newspaper Article 		Add to My Research

Exploring the Gout Pipeline in 2023: FDA Approvals, Promising Therapies, and Key Players Identified by DelveInsight | TaiwanJ Pharmaceuticals, Nippon Chemiphar, HemoShear Horizon Therapeutics plc

M2 Presswire, 2023-12-06

COPYRIGHT 2023 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by
20
Glioma Pipeline Drugs Analysis Report : FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, AbbVie, Inc., Amgen, Inc., Arbor Pharmaceuticals
Glioma Pipeline Drugs Analysis Report : FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, AbbVie, Inc., Amgen, Inc., Arbor Pharmaceuticals
Material Type:
Newspaper Article 		Add to My Research

Glioma Pipeline Drugs Analysis Report : FDA Approvals, Clinical Trials, Therapies, MOA, ROA by DelveInsight | Pfizer, AbbVie, Inc., Amgen, Inc., Arbor Pharmaceuticals

M2 Presswire, 2023-12-04

COPYRIGHT 2023 Normans Media Ltd.

Digital Resources/Online E-Resources

Citations Cited by

Results 1 - 20 of 204  for All Library Resources

Sorted by: Sorted by: RelevanceOr hit Enter to replace sort method
Results 1 2 3 4 5 next page

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To
Refine
  1. Before 2010  (2)
  2. 2010 To 2011  (23)
  3. 2012 To 2013  (26)
  4. 2014 To 2018  (9)
  5. After 2018  (145)
  6. More options open sub menu
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait